OGN - Organon & Co.
NYSE
->
Healthcare
->
Drug Manufacturers—General
Jersey City,
United States
Type: Equity
OGN price evolution
OGN
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1685 | $1617 | $1547 | $1744 |
| Inventory | $1383 | $1287 | $1263 | $1315 |
| Total current assets | $4756 | $4509 | $4196 | $4508 |
| Long term investments | ||||
| Property, plant & equipment | $1204 | $1162 | $1180 | $1356 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $12752 | $12154 | $11891 | $12058 |
| Current liabilities | ||||
| Accounts payable | $1092 | $1243 | $955 | $1314 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2790 | $2755 | $2545 | $2918 |
| Long term debt | $8739 | $8647 | $8705 | $8751 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $12259 | $12010 | $11843 | $12128 |
| Shareholders' equity | ||||
| Retained earnings | $975 | $690 | $573 | $443 |
| Other shareholder equity | -$571 | -$612 | -$577 | -$541 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jul 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $172.31 | |||
| Short term investments | ||||
| Net receivables | $1857 | $1585 | $1497 | $395.13 |
| Inventory | $1315 | $1003 | $915 | $188.78 |
| Total current assets | $4508 | $3931 | $3760 | $796.5 |
| Long term investments | $40.65 | |||
| Property, plant & equipment | $1356 | $1233 | $1203 | $149.19 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $6542 | |||
| Total investments | ||||
| Total assets | $12058 | $10955 | $10681 | $1232.37 |
| Current liabilities | ||||
| Accounts payable | $1314 | $1132 | $1382 | $487.92 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2918 | $2512 | $2597 | $637.43 |
| Long term debt | $8751 | $8905 | $9125 | $207.15 |
| Total noncurrent liabilities | $1950 | |||
| Total debt | ||||
| Total liabilities | $12128 | $11847 | $12189 | $920.05 |
| Shareholders' equity | ||||
| Retained earnings | $443 | -$331 | -$998 | $398.23 |
| Other shareholder equity | -$541 | -$564 | -$513 | -$247.66 |
| Total shareholder equity | $312.33 | |||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1582 | $1607 | $1622 | $1598 |
| Cost of revenue | ||||
| Gross Profit | $923 | $939 | $957 | $915 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $533 | $559 | $546 | $607 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$152 | $40 | $35 | -$442 |
| Interest expense | -$132 | -$130 | -$137 | -$146 |
| Net income | ||||
| Net income | $359 | $195 | $201 | $546 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jul 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6263 | $6174 | $1589.14 | |
| Cost of revenue | $1359.55 | |||
| Gross Profit | $3748 | $3930 | $229.59 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $185.5 | |||
| Total operating expenses | $2436 | $2190 | $1554.43 | |
| Operating income | $34.71 | |||
| Income from continuing operations | ||||
| EBIT | $34.71 | |||
| Income tax expense | -$350 | $205 | $3.26 | |
| Interest expense | -$569 | -$433 | -$12.2 | |
| Net income | ||||
| Net income | $1023 | $917 | $19.86 | |
| Income (for common shares) | $19.86 | |||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$217 | -$142 | -$96 | -$260 |
| Financing activities | ||||
| Dividends paid | -$223 | -$149 | -$70 | -$294 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$286 | -$208 | -$74 | -$569 |
| Effect of exchange rate | $24 | -$47 | -$24 | $17 |
| Change in cash and equivalents | $70 | $11 | -$118 | -$13 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jul 2020 |
|---|---|---|---|---|
| Net income | $19.86 | |||
| Operating activities | ||||
| Depreciation | $25.59 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $75.41 | |||
| Investing activities | ||||
| Capital expenditures | -$12.06 | |||
| Investments | $1.02 | |||
| Total cash flows from investing | -$260 | -$420 | -$481 | -$15.33 |
| Financing activities | ||||
| Dividends paid | -$294 | -$290 | -$145 | -$26.78 |
| Sale and purchase of stock | ||||
| Net borrowings | $29.07 | |||
| Total cash flows from financing | -$569 | -$433 | -$1333 | $2.29 |
| Effect of exchange rate | $17 | -$36 | $23 | $2.42 |
| Change in cash and equivalents | -$13 | -$31 | $667 | $64.79 |
News
Fundamentals
| Market cap | $2.33B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 257.54M |
| Revenue | $6.41B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $1.30B |
| Revenue Q/Q | 2.93% |
| Revenue Y/Y | N/A |
| P/E ratio | 1.79 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.36 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $5.05 |
|---|---|
| ROA | 10.65% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.70 |
| Quick ratio | 1.21 |